SOFMEREE
Notice Of Allowance - Issued
Status timeline
- 15 Apr 2026Application filedNew Application Entered
- 12 May 2026Assigned to an examining attorneyAssigned To Examiner
- 14 May 2026Approved for publicationApproved For Pub - Principal Register
- 9 Jun 2026Published for oppositionPublished For Opposition
- 4 Aug 2026Notice of allowance issued — statement of use requiredNoa E-Mailed - Sou Required From Applicant
All 9 USPTO events
| 2026-08-04 | Noa E-Mailed - Sou Required From Applicant |
| 2026-06-09 | Published For Opposition |
| 2026-06-09 | Official Gazette Publication Confirmation E-Mailed |
| 2026-06-03 | Notification Of Notice Of Publication E-Mailed |
| 2026-05-14 | Approved For Pub - Principal Register |
| 2026-05-12 | Assigned To Examiner |
| 2026-04-15 | New Application Entered |
| 2026-04-15 | New Application Office Supplied Data Entered |
| 2026-04-15 | Application Filing Receipt Mailed |
Goods & services
Class 5 Pharmaceuticals & supplements
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer’s disease, asthma, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular disease, central nervous system diseases and disorders, Crohn’s disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, m…
Source & freshness
Source: USPTO Trademark Applications bulk data. This record was last updated by the USPTO file dated 4 Aug 2026; the index was built on 20 Nov 2026 and covers USPTO data through 31 Aug 2026. Open the official USPTO record (TSDR) → If the two differ, the USPTO record is correct.